Susan E Morgan-Lappe (Susan Morgan-Lappe)

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 3

Top Topics

Top Venues

Molecular cancer therapeutics

Cancer research

This page only lists publications with an associated author ORCID identifier.

Publications

Shweta Singh, Laura Serwer, Amy DuPage, Kristi Elkins, Niharika Chauhan, Matthew Ravn, Fritz Buchanan, Leyu Wang, Michael Krimm, Ken Wong, Jason Sagert, Kimberly Tipton, Stephen J Moore, Yuanhui Huang, Andrew Jang, Eric Ureno, Adam Miller, Sarah Patrick, Shanti Duvur, Shouchun Liu, Olga Vasiljeva, Yingchun Li, Tracy Henriques, Ilaria Badagnani, Shawn Jeffries, Siew Schleyer, Rob Leanna, Claus Krebber, Sridhar Viswanathan, Luc Desnoyers, Jonathan Terrett, Marcia Belvin, Susan E Morgan-Lappe, W Michael Kavanaugh, Jennifer Richardson
Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate. Molecular cancer therapeutics 21 (8) (2022)
Darren C Phillips, Fritz G Buchanan, Dong Cheng, Larry R Solomon, Yu Xiao, John Xue, Stephen K Tahir, Morey L Smith, Haichao Zhang, Deborah Widomski, Vivek C Abraham, Nan Xu, Zhihong Liu, Li Zhou, Enrico DiGiammarino, Xin Lu, Nandini Rudra-Ganguly, Bruce Trela, Susan E Morgan-Lappe
Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors. Cancer research 81 (12) (2021)
Michael S Gordon, John J Nemunaitis, Minal Barve, Zev A Wainberg, Erika P Hamilton, Ramesh K Ramanathan, George W Sledge, Huibin Yue, Susan E Morgan-Lappe, Martha Blaney, Sreeneeranj Kasichayanula, Monica Motwani, Lan Wang, Louie Naumovski, John H Strickler
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors. Molecular cancer therapeutics 20 (10) (2021)